Azitra (AZTR) Income towards Parent Company (2022 - 2026)
Azitra (AZTR) posted Income towards Parent Company of -$3.9 million for Q1 2026, down 75.83% on a QoQ basis from -$2.2 million in Q4 2025, and down 27.99% year-over-year from -$5.5 million in Q1 2025.
Azitra (AZTR) Income towards Parent Company (2022 - 2026) Analysis & Trends
Azitra's Income towards Parent Company history runs 5 years deep, the most recent figure standing at -$3.9 million for Q1 2026.
- Quarterly Income towards Parent Company fell 27.99% year-over-year to -$3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.8 million (down 29.78% YoY) and the FY2025 annual result came in at -$11.0 million, down 22.17% from the prior year.
- Income towards Parent Company was -$3.9 million for Q1 2026 at Azitra, down from -$2.2 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$1.0 million in Q3 2024 and bottomed at -$4.4 million in Q2 2023.
- A 5-year average of -$2.6 million and a median of -$2.5 million in 2023 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2024 — Income towards Parent Company jumped 48.05% — and 2025, when it slumped 173.85%.
- Azitra's Income towards Parent Company stood at -$2.8 million in 2022, then climbed by 12.46% to -$2.5 million in 2023, then increased by 2.47% to -$2.4 million in 2024, then rose by 6.67% to -$2.2 million in 2025, then tumbled by 75.83% to -$3.9 million in 2026.
- Business Quant data shows AZTR's Income towards Parent Company at -$3.9 million in Q1 2026, -$2.2 million in Q4 2025, and -$2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,792.52 Bn | 1,792.46 Bn | - |
| 2 | Akari Therapeutics | 999.95 Bn | 999.95 Bn | - |
| 3 | BeOne Medicines | 475.97 Bn | 471.17 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 124.91 Bn | 117.66 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 72.31 Bn | 63.56 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.01 Bn | 62.01 Bn | - |
| 7 | Argenx Se | 54.23 Bn | 49.04 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 38.31 Bn | 35.30 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.16 Bn | 36.16 Bn | - |
| 10 | Azitra | 2.05 Mn | 2.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.93 Mn |
| Dec 31, 2025 | -2.23 Mn |
| Sep 30, 2025 | -2.76 Mn |
| Jun 30, 2025 | -2.89 Mn |
| Mar 31, 2025 | -3.07 Mn |
| Dec 31, 2024 | -2.39 Mn |
| Sep 30, 2024 | -1.01 Mn |
| Jun 30, 2024 | -2.63 Mn |
| Mar 31, 2024 | -2.93 Mn |
| Dec 31, 2023 | -2.45 Mn |
| Sep 30, 2023 | -1.94 Mn |
| Jun 30, 2023 | -4.43 Mn |
| Mar 31, 2023 | -2.46 Mn |
| Dec 31, 2022 | -2.80 Mn |
| Sep 30, 2022 | -2.40 Mn |
| Jun 30, 2022 | -1.89 Mn |